{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:35:44Z","timestamp":1784864144120,"version":"3.55.0"},"reference-count":47,"publisher":"American Society of Hematology","issue":"13","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,25]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Children with Down syndrome (DS) have a high risk of GATA1-associated myeloid leukemia (ML-DS) before age 4 years. Somatic N-terminal GATA1 mutations (GATA1s) are necessary, but not sufficient, for ML-DS, but their significance at birth for individual babies and whether mutations occur after birth is unclear. To address these questions, we performed a prospective study of newborns with DS using next-generation sequencing-based GATA1 mutation analysis, with hematologic and clinical evaluation and follow-up for the window of ML-DS risk. Of 450 neonates with DS, 113 (25%) had GATA1s mutations, among whom 20\/113 (17.7%) had multiple mutations and 59 (52%) were clinically silent. Variant allele frequency (VAF) varied from 0.3% to 89%. VAF positively correlated (P &amp;lt; .0001) with the percent blasts, leukocytes, dyserythropoiesis and dysmegakaryopoiesis scores, and clinical disease severity, and negatively with hemoglobin, although only 4\/113 were anemic. GATA1s mutations were detected from 28 weeks gestation; the highest frequency (45%) was at 34 to 35 weeks, whereas mutation frequency in early fetal samples (&amp;lt;20 weeks) was &amp;lt;4% (2\/57). GATA1s clones (VAF, percent blasts) fell rapidly postnatally, becoming undetectable by 6 months, except in neonates who developed ML-DS. Of 110 surviving neonates, 7 (6.4%) developed ML-DS at a median age of 17.5 months. GATA1s clone size at birth was the only predictor of ML-DS. No neonates lacking GATA1s mutations acquired mutations after birth or developed ML-DS. Taken together, the fetal environment is essential for GATA1s mutation selection and expansion of GATA1s clones. Rates of leukemic transformation of GATA1s clones detected at birth are low, but clones that persist &amp;gt;6 months transformed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2025029250","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T14:47:56Z","timestamp":1750862876000},"page":"1561-1574","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Clinical significance of preleukemic somatic <i>GATA1<\/i> mutations in children with Down syndrome"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6713-7349","authenticated-orcid":false,"given":"Natalina","family":"Elliott","sequence":"first","affiliation":[{"name":"1Department of Paediatrics, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom"},{"name":"2MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Bhatnagar","sequence":"additional","affiliation":[{"name":"1Department of Paediatrics, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom"},{"name":"3Centre for Haematology, Imperial College London, London, United Kingdom"},{"name":"4Children\u2019s Hospital, Oxford University Hospital NHS Foundation Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Buck","sequence":"additional","affiliation":[{"name":"1Department of Paediatrics, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom"},{"name":"2MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cruz Hernandez","sequence":"additional","affiliation":[{"name":"2MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Perkins","sequence":"additional","affiliation":[{"name":"2MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4880-7543","authenticated-orcid":false,"given":"Adam J.","family":"de Smith","sequence":"additional","affiliation":[{"name":"5Center for Genetic Epidemiology, Keck School of Medicine of University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4573-9712","authenticated-orcid":false,"given":"Amelie","family":"Chaussade","sequence":"additional","affiliation":[{"name":"1Department of Paediatrics, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Nizery","sequence":"additional","affiliation":[{"name":"1Department of Paediatrics, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1806-0952","authenticated-orcid":false,"given":"Marlen","family":"Metzner","sequence":"additional","affiliation":[{"name":"2MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Garnett","sequence":"additional","affiliation":[{"name":"2MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Norton","sequence":"additional","affiliation":[{"name":"6Department of Haematology, Birmingham Women\u2019s and Children\u2019s NHS Foundation Trust, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Kennedy","sequence":"additional","affiliation":[{"name":"2MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Triya","family":"Chakravorty","sequence":"additional","affiliation":[{"name":"1Department of Paediatrics, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2612-1112","authenticated-orcid":false,"given":"Dylan","family":"Zhao","sequence":"additional","affiliation":[{"name":"7Oxford Medical Schools Division, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2551-2278","authenticated-orcid":false,"given":"Lars","family":"Hanssen","sequence":"additional","affiliation":[{"name":"2MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Hall","sequence":"additional","affiliation":[{"name":"1Department of Paediatrics, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom"},{"name":"4Children\u2019s Hospital, Oxford University Hospital NHS Foundation Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3931-0914","authenticated-orcid":false,"given":"Paresh","family":"Vyas","sequence":"additional","affiliation":[{"name":"2MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom"},{"name":"8Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom"},{"name":"9Department of Haematology, Oxford University Hospitals NHS Trust and Oxford Biomedical Centre, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6094-6397","authenticated-orcid":false,"given":"Irene","family":"Roberts","sequence":"additional","affiliation":[{"name":"1Department of Paediatrics, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom"},{"name":"2MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9199","key":"2025092511212996500_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(99)05264-2","article-title":"Risks of leukaemia and solid tumours in individuals with Down\u2019s syndrome","volume":"355","author":"Hasle","year":"2000","journal-title":"Lancet"},{"issue":"11","key":"2025092511212996500_bib2","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/gim.2016.23","article-title":"Low risk of solid tumors in persons with Down syndrome","volume":"18","author":"Hasle","year":"2016","journal-title":"Genet Med"},{"key":"2025092511212996500_bib3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jpeds.2021.03.001","article-title":"Leukemia risk in a cohort of 3.9 million children with and without Down syndrome","volume":"234","author":"Marlow","year":"2021","journal-title":"J Pediatr"},{"issue":"7","key":"2025092511212996500_bib4","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of hematolymphoid tumors: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"2025092511212996500_bib5","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1046\/j.1365-2141.2003.04229.x","article-title":"Transient leukaemia \u2013 a benign form of leukaemia in newborn infants with trisomy 21","volume":"120","author":"Zipursky","year":"2003","journal-title":"Br J Haematol"},{"issue":"6","key":"2025092511212996500_bib6","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood-2007-10-118810","article-title":"Treatment and prognostic impact of transient leukemia in neonates with Down syndrome","volume":"111","author":"Klusmann","year":"2008","journal-title":"Blood"},{"issue":"26","key":"2025092511212996500_bib7","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1182\/blood-2011-04-350017","article-title":"Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children\u2019s Oncology Group Study A2971","volume":"118","author":"Gamis","year":"2011","journal-title":"Blood"},{"issue":"24","key":"2025092511212996500_bib8","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2013-07-515148","article-title":"GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia","volume":"122","author":"Roberts","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2025092511212996500_bib9","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng955","article-title":"Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome","volume":"32","author":"Wechsler","year":"2002","journal-title":"Nat Genet"},{"issue":"11","key":"2025092511212996500_bib10","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2002-12-3904","article-title":"Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis","volume":"101","author":"Mundschau","year":"2003","journal-title":"Blood"},{"issue":"11","key":"2025092511212996500_bib11","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1182\/blood-2003-01-0013","article-title":"GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome","volume":"101","author":"Hitzler","year":"2003","journal-title":"Blood"},{"issue":"3","key":"2025092511212996500_bib12","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2002-11-3599","article-title":"Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21","volume":"102","author":"Rainis","year":"2003","journal-title":"Blood"},{"issue":"8","key":"2025092511212996500_bib13","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2003-02-0390","article-title":"Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome","volume":"102","author":"Xu","year":"2003","journal-title":"Blood"},{"issue":"9369","key":"2025092511212996500_bib14","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(03)13266-7","article-title":"Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder","volume":"361","author":"Groet","year":"2003","journal-title":"Lancet"},{"issue":"7","key":"2025092511212996500_bib15","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood-2003-10-3383","article-title":"Natural history of GATA1 mutations in Down syndrome","volume":"103","author":"Ahmed","year":"2004","journal-title":"Blood"},{"issue":"11","key":"2025092511212996500_bib16","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/ng.2759","article-title":"The landscape of somatic mutations in Down syndrome-related myeloid disorders","volume":"45","author":"Yoshida","year":"2013","journal-title":"Nat Genet"},{"issue":"2","key":"2025092511212996500_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccell.2019.06.007","article-title":"Mechanisms of progression of myeloid preleukemia to transformed myeloid leukemia in children with down syndrome","volume":"36","author":"Labuhn","year":"2019","journal-title":"Cancer Cell"},{"issue":"25","key":"2025092511212996500_bib18","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood.2023022247","article-title":"Landscape of driver mutations and their clinical effects on Down syndrome-related myeloid neoplasms","volume":"143","author":"Sato","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2025092511212996500_bib19","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/ng1825","article-title":"An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis","volume":"38","author":"Hollanda","year":"2006","journal-title":"Nat Genet"},{"issue":"17","key":"2025092511212996500_bib20","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/bioinformatics\/btp373","article-title":"VarScan: variant detection in massively parallel sequencing of individual and pooled samples","volume":"25","author":"Koboldt","year":"2009","journal-title":"Bioinformatics"},{"issue":"6","key":"2025092511212996500_bib21","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/leu.2013.373","article-title":"GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia","volume":"28","author":"Maroz","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"2025092511212996500_bib22","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/ng1566","article-title":"Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1","volume":"37","author":"Li","year":"2005","journal-title":"Nat Genet"},{"issue":"7","key":"2025092511212996500_bib23","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1172\/JCI63597","article-title":"Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia","volume":"122","author":"Sankaran","year":"2012","journal-title":"J Clin Invest"},{"issue":"6","key":"2025092511212996500_bib24","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2012-10-460998","article-title":"Perturbation of fetal hematopoiesis in a mouse model of Down syndrome\u2019s transient myeloproliferative disorder","volume":"122","author":"Birger","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2025092511212996500_bib25","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1172\/JCI75714","article-title":"Pluripotent stem cells reveal erythroid-specific activities of the GATA1 N-terminus","volume":"125","author":"Byrska-Bishop","year":"2015","journal-title":"J Clin Invest"},{"issue":"5","key":"2025092511212996500_bib26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3324\/haematol.2014.112714","article-title":"Global transcriptome and chromatin occupancy analysis reveal the short isoform of GATA1 is deficient for erythroid specification and gene expression","volume":"100","author":"Chlon","year":"2015","journal-title":"Haematologica"},{"issue":"6","key":"2025092511212996500_bib27","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.celrep.2016.04.031","article-title":"Systematic cellular disease models reveal synergistic interaction of trisomy 21 and GATA1 mutations in hematopoietic abnormalities","volume":"15","author":"Banno","year":"2016","journal-title":"Cell Rep"},{"issue":"19","key":"2025092511212996500_bib28","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2019001234","article-title":"Chromatin occupancy and epigenetic analysis reveal new insights into the function of the GATA1 N terminus in erythropoiesis","volume":"134","author":"Ling","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2025092511212996500_bib29","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3324\/haematol.2019.244541","article-title":"Oncogenic Gata1 causes stage-specific megakaryocyte differentiation delay","volume":"106","author":"Juban","year":"2021","journal-title":"Haematologica"},{"issue":"13","key":"2025092511212996500_bib30","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood-2008-11-190330","article-title":"Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome","volume":"114","author":"Cabelof","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2025092511212996500_bib31","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1182\/blood-2011-03-342774","article-title":"Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia","volume":"118","author":"Alford","year":"2011","journal-title":"Blood"},{"key":"2025092511212996500_bib32","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1017\/erm.2021.6","article-title":"Increased risk of leukaemia in children with Down syndrome- a somatic evolutionary view","volume":"23","author":"Hasaart","year":"2021","journal-title":"Expert Rev Mol Med"},{"issue":"22","key":"2025092511212996500_bib33","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1182\/blood-2010-05-282426","article-title":"Down syndrome and GATA1 mutations in transient myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia","volume":"116","author":"Kanezaki","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2025092511212996500_bib34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/archdischild-2014-308004","article-title":"Prenatal therapy in transient abnormal myelopoiesis: a systematic review","volume":"101","author":"Tamblyn","year":"2016","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"5","key":"2025092511212996500_bib35","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/s41375-021-01171-y","article-title":"Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome","volume":"35","author":"Yamato","year":"2021","journal-title":"Leukemia"},{"issue":"13","key":"2025092511212996500_bib36","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/bloodadvances.2018018945","article-title":"Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD prevention 2007 study","volume":"2","author":"Flasinski","year":"2018","journal-title":"Blood Adv"},{"issue":"6","key":"2025092511212996500_bib37","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1055\/a-1532-2016","article-title":"Recommendations for the diagnosis and treatment of children with transient abnormal myelopoiesis (TAM) and myeloid leukemia in Down syndrome (ML-DS)","volume":"233","author":"Al-Kershi","year":"2021","journal-title":"Klin Padiatr"},{"issue":"5","key":"2025092511212996500_bib38","doi-asserted-by":"crossref","first-page":"e2022057010","DOI":"10.1542\/peds.2022-057010","article-title":"Health supervision for children and adolescents with Down syndrome","volume":"149","author":"Bull","year":"2022","journal-title":"Pediatrics"},{"issue":"6551","key":"2025092511212996500_bib39","doi-asserted-by":"crossref","first-page":"eabf6202","DOI":"10.1126\/science.abf6202","article-title":"Mapping the cellular origin and early evolution of leukemia in Down syndrome","volume":"373","author":"Wagenblast","year":"2021","journal-title":"Science"},{"issue":"12","key":"2025092511212996500_bib40","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood.2020005610","article-title":"Sensitive, rapid diagnostic test for transient abnormal myelopoiesis and myeloid leukemia of Down syndrome","volume":"136","author":"Cruz Hernandez","year":"2020","journal-title":"Blood"},{"issue":"8","key":"2025092511212996500_bib41","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/s41375-021-01128-1","article-title":"Sensitive GATA1 mutation screening reliably identifies neonates with Down syndrome at risk for myeloid leukemia","volume":"35","author":"Goemans","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"2025092511212996500_bib42","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/ijlh.13756","article-title":"Sensitive detection of GATA1 mutations using complementary DNA-based analysis for transient abnormal myelopoiesis associated with the Down syndrome","volume":"44","author":"Mizuta","year":"2022","journal-title":"Int J Lab Hematol"},{"issue":"2","key":"2025092511212996500_bib43","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/bjh.15390","article-title":"Guidelines for the investigation and management of transient leukaemia of Down syndrome","volume":"182","author":"Tunstall","year":"2018","journal-title":"Br J Haematol"},{"issue":"8032","key":"2025092511212996500_bib44","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41586-024-07946-4","article-title":"Single-cell multi-omics map of human fetal blood in Down syndrome","volume":"634","author":"Marderstein","year":"2024","journal-title":"Nature"},{"issue":"1","key":"2025092511212996500_bib45","doi-asserted-by":"crossref","first-page":"12991","DOI":"10.1038\/s41598-020-69822-1","article-title":"Mutation accumulation and developmental lineages in normal and Down syndrome human fetal hematopoiesis","volume":"10","author":"Hasaart","year":"2020","journal-title":"Sci Rep"},{"issue":"3","key":"2025092511212996500_bib46","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41375-024-02151-8","article-title":"Inherent genome instability underlies trisomy 21-associated myeloid malignancies","volume":"38","author":"Chen","year":"2024","journal-title":"Leukemia"},{"issue":"16","key":"2025092511212996500_bib47","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1182\/bloodadvances.2025016282","article-title":"Genome-wide association study of somatic GATA1s mutations in newborns with Down syndrome","volume":"9","author":"Li","year":"2025","journal-title":"Blood Adv"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/13\/1561\/2413127\/blood_bld-2025-029250-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/13\/1561\/2413127\/blood_bld-2025-029250-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:21:37Z","timestamp":1758813697000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/13\/1561\/537925\/Clinical-significance-of-preleukemic-somatic-GATA1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":47,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,9,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025029250","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,25]]},"published":{"date-parts":[[2025,9,25]]}}}